|
1
|
Barnes L, Eveson JW, Reichart P and
Sidransky D: Tumor of the oral cavity and oropharynx. Pathology and
Genetics of Head and Neck Tumours (World Health Organization
Classification of Tumours) (Lyon). IARC Press. 2005.
|
|
2
|
Roopashree MR, Gondhalekar RV, Shashikanth
MC, George J, Thippeswamy SH and Shukla A: Pathogenesis of oral
lichen planus - a review. J Oral Pathol Med. 39:729–734. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farhi D and Dupin N: Pathophysiology,
etiologic factors and clinical management of oral lichen planus,
part I: facts and controversies. Clin Dermatol. 28:100–108. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ismail SB, Kumar SK and Zain RB: Oral
lichen planus and lichenoid reactions: etiopathogenesis, diagnosis,
management and malignant transformation. J Oral Sci. 49:89–106.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parashar P: Oral lichen planus.
Otolaryngol Clin North Am. 44:89–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McCartan BE and Healy CM: The reported
prevalence of oral lichen planus: a review and critique. J Oral
Pathol Med. 37:447–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kramer IR, Lucas RB, Pindborg JJ and Sobin
LH: Definition of leukoplakia and related lesions: an aid to
studies on oral precancer. Oral Surg Oral Med Oral Pathol.
46:518–539. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Silverman S Jr..Gorsky M and Lozada-Nur F:
A prospective follow-up study of 570 patients with oral lichen
planus: persistence, remission and malignant association. Oral Surg
Oral Med Oral Pathol. 60:30–34. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murti PR, Daftary DK, Bhonsle RB, Gupta
PC, Mehta FS and Pindborg JJ: Malignant potential of oral lichen
planus: observations in 722 patients from India. J Oral Pathol.
15:71–77. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Silverman S Jr, Gorsky M, Lozada-Nur F and
Giannotti K: A prospective study of findings and management in 214
patients with oral lichen planus. Oral Surg Oral Med Oral Pathol.
72:665–670. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sigurgeirsson B and Lindelöf B: Lichen
planus and malignancy. An epidemiologic study of 2071 patients and
a review of the literature. Arch Dermatol. 127:1684–1688. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Meij EH, Mast H and van der Waal
I: The possible premalignant character of oral lichen planus and
oral lichenoid lesions: a prospective five-year follow-up study of
192 patients. Oral Oncol. 43:742–748. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mignogna MD, Fedele S, Lo Russo L, Lo
Muzio L and Bucci E: Immune activation and chronic inflammation as
the cause of malignancy in oral lichen planus: is there any
evidence? Oral Oncol. 40:120–130. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lodi G, Scully C, Carrozzo M, Griffiths M,
Sugerman PB and Thongprasom K: Current controversies in oral lichen
planus: report of an international consensus meeting. Part 2.
Clinical management and malignant transformation. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 100:164–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sousa FA, Paradella TC, Carvalho YR and
Rosa LE: Immunohistochemical expression of PCNA, p53, bax and bcl-2
in oral lichen planus and epithelial dysplasia. J Oral Sci.
51:117–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Sousa FA, Paradella TC, Carvalho YR and
Rosa LE: Comparative analysis of the expression of proliferating
cell nuclear antigen, p53, bax and bcl-2 in oral lichen planus and
oral squamous cell carcinoma. Ann Diagn Pathol. 13:308–312. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagata S: Apoptosis by death factor. Cell.
88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuwana T, Bouchier-Hayes L, Chipuk JE,
Bonzon C, Sullivan BA, Green DR and Newmeyer DD: BH3 domains of
BH3-only proteins differentially regulate Bax-mediated
mitochondrial membrane permeabilization both directly and
indirectly. Mol Cell. 17:525–535. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jordan RC, Catzavelos GC, Barrett AW and
Speight PM: Differential expression of bcl-2 and bax in squamous
cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol.
32B:394–400. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh BB, Chandler FW Jr, Whitaker SB and
Forbes-Nelson AE: Immunohistochemical evaluation of bcl-2
oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 85:692–698. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sulkowska M, Famulski W, Chyczewski L and
Sulkowski S: Evaluation of p53 and bcl-2 oncoprotein expression in
precancerous lesions of the oral cavity. Neoplasma. 48:94–98.
2001.PubMed/NCBI
|
|
22
|
Warr MR and Shore GC: Unique biology of
Mcl-1: therapeutic opportunities in cancer. Curr Mol Med.
8:138–147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mallick S, Patil R, Gyanchandani R, Pawar
S, Palve V, Kannan S, Pathak KA, Choudhary M and Teni TR: Human
oral cancers have altered expression of Bcl-2 family members and
increased expression of the anti-apoptotic splice variant of Mcl-1.
J Pathol. 217:398–407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shin JA, Jung JY, Ryu MH, Safe S and Cho
SD: Mithramycin A inhibits myeloid cell leukemia-1 to induce
apoptosis in oral squamous cell carcinomas and tumor xenograft
through activation of Bax and oligomerization. Mol Pharmacol.
83:33–41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leyva-Huerta ER, Ledesma-Montes C,
Rojo-Botello RE and Vega-Memije E: P53 and bcl-2 immunoexpression
in patients with oral lichen planus and oral squamous cell
carcinoma. Med Oral Patol Oral Cir Bucal. 17:e745–e750. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagata M, Wada K, Nakajima A, Nakajima N,
Kusayama M, Masuda T, Iida S, Okura M, Kogo M and Kamisaki Y: Role
of myeloid cell leukemia-1 in cell growth of squamous cell
carcinoma. J Pharmacol Sci. 110:344–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang S, Okumura K and Sinicrope FA: BH3
mimetic obatoclax enhances TRAIL-mediated apoptosis in human
pancreatic cancer cells. Clin Cancer Res. 15:150–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rahmani M, Davis EM, Bauer C, Dent P and
Grant S: Apoptosis induced by the kinase inhibitor BAY 43–9006 in
human leukemia cells involves down-regulation of Mcl-1 through
inhibition of translation. J Biol Chem. 280:35217–35227. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu HJ, Shin JA, Jung JY, Nam JS, Hong IS,
Cho NP and Cho SD: Inhibition of myeloid cell leukemia-1:
Association with sorafenib-induced apoptosis in human
mucoepidermoid carcinoma cells and tumor xenograft. Head Neck.
37:1326–1335. 2015. View Article : Google Scholar : PubMed/NCBI
|
